MedTrace Logo

High Resolution PET-MRI Before Prostate Cancer HIFU

NCT03263780 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2021-02-21

Study results available
· View outcomes & findings →

Summary

This prospective trial aims to determine if enhanced prostate imaging using two novel imaging technologies (high resolution DWI and 18F-fluciclovine PET-MRI) will detect prostate cancers not seen on standard multiparametric prostate MRI in patients considered candidates for focal HIFU.

Conditions

Interventions

DRUG

18F-Fluciclovine

Imaging (comparing standard and experimental high resolution diffusion-weighted imaging \[DWI\] MRI with 18F-Fluciclovine)

Sponsors & Collaborators

  • Blue Earth Diagnostics

    collaborator INDUSTRY

  • Timothy J. Daskivich

    lead OTHER

Principal Investigators

  • Timothy Daskivich, MD · Cedars-Sinai Medical Center

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-07
Primary Completion
2020-01-08
Completion
2020-01-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03263780 on ClinicalTrials.gov